Key statistics dashboard for Artelo Biosciences, Inc. (ARTL). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory...
Stock Data
| Price | $3.75 |
| Market Cap | $1M |
| Beta | 0.41 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.05 |
| Price / Book | 0.23 |
| P/S | 0.00 |
| P/FCF | -0.11 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 3.00 |
| Quick Ratio | 3.00 |
| Cash Ratio | 2.89 |
| Debt / Equity | 0.01 |
| Debt / Assets | 0.76% |
| Interest Coverage | -17.91 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -45.94 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 16.58 |
| Cash per share | 13.93 |
| FCF per share | -41.92 |
| Tangible Book Value per share | 9.82 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 0.50 |
Related companies: CARM · GTBP · LIPO · PBM · PTIX · REVB · SLRX
Explore sector: Healthcare · Biotechnology
More sections of ARTL: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks